HK1191938A1 - Indazolyl triazole derivatives as irak inhibitors -1 - Google Patents
Indazolyl triazole derivatives as irak inhibitors -1Info
- Publication number
- HK1191938A1 HK1191938A1 HK14105096.6A HK14105096A HK1191938A1 HK 1191938 A1 HK1191938 A1 HK 1191938A1 HK 14105096 A HK14105096 A HK 14105096A HK 1191938 A1 HK1191938 A1 HK 1191938A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- triazole derivatives
- irak inhibitors
- indazolyl
- indazolyl triazole
- irak
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061424890P | 2010-12-20 | 2010-12-20 | |
EP10195867 | 2010-12-20 | ||
PCT/EP2011/073015 WO2012084704A1 (fr) | 2010-12-20 | 2011-12-16 | Dérivés d'indazolyl triazole en tant qu'inhibiteurs d'irak |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1191938A1 true HK1191938A1 (en) | 2014-08-08 |
Family
ID=43838132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14105096.6A HK1191938A1 (en) | 2010-12-20 | 2014-05-30 | Indazolyl triazole derivatives as irak inhibitors -1 |
Country Status (24)
Country | Link |
---|---|
US (1) | US9073892B2 (fr) |
EP (1) | EP2655357B1 (fr) |
JP (1) | JP6007189B2 (fr) |
KR (1) | KR101842098B1 (fr) |
CN (1) | CN103429585B (fr) |
AR (1) | AR084507A1 (fr) |
AU (1) | AU2011347711B2 (fr) |
BR (2) | BR112013015460B1 (fr) |
CA (1) | CA2822166C (fr) |
EA (1) | EA023544B1 (fr) |
ES (1) | ES2592713T3 (fr) |
HK (1) | HK1191938A1 (fr) |
HR (1) | HRP20161127T1 (fr) |
HU (1) | HUE029617T2 (fr) |
IL (1) | IL226912A (fr) |
LT (1) | LT2655357T (fr) |
MX (1) | MX2013007149A (fr) |
PL (1) | PL2655357T3 (fr) |
PT (1) | PT2655357T (fr) |
RS (1) | RS55165B1 (fr) |
SG (1) | SG191205A1 (fr) |
SI (1) | SI2655357T1 (fr) |
WO (1) | WO2012084704A1 (fr) |
ZA (1) | ZA201305483B (fr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
ME03300B (fr) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Composés tricycliques substitués servant d'inhibiteurs des fgfr |
US9643955B2 (en) | 2012-12-20 | 2017-05-09 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists |
EP2934516A4 (fr) | 2012-12-20 | 2016-07-20 | Merck Sharp & Dohme | Antagonistes des récepteurs de l'orexine 3-ester-4-substitués |
CA2900442C (fr) * | 2013-02-07 | 2021-09-21 | Merck Patent Gmbh | Derives de pyridazinone macrocycliques |
JP6483624B2 (ja) * | 2013-02-07 | 2019-03-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ピリダジノン−アミド誘導体 |
DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
US10160753B2 (en) | 2014-01-10 | 2018-12-25 | Aurigene Discovery Technologies Limited | Indazole compounds as IRAK4 inhibitors |
PT3466955T (pt) | 2014-01-13 | 2021-01-29 | Aurigene Discovery Tech Ltd | Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro |
US9926330B2 (en) | 2014-09-30 | 2018-03-27 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
EP3200789B1 (fr) | 2014-09-30 | 2019-11-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité d'irak4 |
EP3200790B1 (fr) | 2014-09-30 | 2020-08-26 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité d'irak4 |
JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
WO2016096709A1 (fr) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Dérivés hétérocycliques modulant l'activité de certaines protéines kinases |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
BR112017022349B1 (pt) | 2015-04-22 | 2023-11-07 | Rigel Pharmaceuticals, Inc | Composto, composição o compreendendo, seus usos, e, método |
EP3195865A1 (fr) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Combinaisons d'inhibiteurs d'irak4 et inhibiteurs de btk |
TW201701879A (zh) | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Irak4抑制劑組合 |
EP3423446B1 (fr) | 2016-03-03 | 2020-09-16 | Bayer Pharma Aktiengesellschaft | Nouveaux indazoles substitués en 2, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour produire des médicaments |
EP3219329A1 (fr) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinaisons de copanlisib |
MA44759B1 (fr) | 2016-04-29 | 2024-01-31 | Bayer Pharma AG | Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide |
SG11201808686VA (en) | 2016-04-29 | 2018-11-29 | Bayer Pharma AG | Synthesis of indazoles |
UA124237C2 (uk) | 2016-06-01 | 2021-08-11 | Байєр Енімал Хелс Гмбх | Заміщені індазоли, придатні для лікування і попередження алергійних і/або запальних захворювань у тварин |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
HRP20230657T8 (hr) | 2017-03-31 | 2023-11-10 | Aurigene Oncology Limited | Spojevi i pripravci za liječenje hematoloških poremećaja |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3684366A4 (fr) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Ligands crbn et utilisations de ces derniers |
AU2018338314A1 (en) | 2017-09-22 | 2020-04-09 | Kymera Therapeutics, Inc | Protein degraders and uses thereof |
WO2019076817A1 (fr) | 2017-10-19 | 2019-04-25 | Bayer Animal Health Gmbh | Utilisation de pyrrolidones hétéroaromatiques fusionnées pour le traitement et la prévention de maladies chez des animaux |
SG11202002386WA (en) | 2017-10-31 | 2020-04-29 | Curis Inc | Compounds and compositions for treating hematological disorders |
WO2019111218A1 (fr) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs d'irak4 |
US10874743B2 (en) | 2017-12-26 | 2020-12-29 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
EP3737675A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Ligands crbn et leurs utilisations |
EP3737666A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et utilisations associées |
GB201801226D0 (en) * | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
TW202136268A (zh) | 2018-07-13 | 2021-10-01 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
BR112021010484A2 (pt) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics, Inc. | Degradadores de irak e usos dos mesmos |
EP3924340A1 (fr) * | 2019-02-11 | 2021-12-22 | Merck Patent GmbH | Dérivés d'indazolyl-isoxazole pour le traitement de maladies telles que le cancer |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JOP20220050A1 (ar) | 2019-08-30 | 2023-01-30 | Rigel Pharmaceuticals Inc | مركبات بيرازول، صياغات منها وطريقة لاستخدام المركبات و/ أو صياغات |
EP4038062A4 (fr) | 2019-10-02 | 2023-10-11 | Kainos Medicine, Inc. | Composé de n-(1h-imidazol-2-yl)benzamide et composition pharmaceutique le comprenant en tant que principe actif |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
CN114599652A (zh) * | 2019-10-31 | 2022-06-07 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
EP4076524A4 (fr) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
BR112022011651A2 (pt) | 2019-12-17 | 2022-08-23 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
KR102607237B1 (ko) * | 2023-06-07 | 2023-11-30 | 주식회사 젠센 | 신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200503242B (en) * | 2002-10-24 | 2006-10-25 | Celgene Corp | Treatment of pain with JNK inhibitors |
US20040087642A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
US20050090529A1 (en) * | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
US20060258706A1 (en) * | 2005-04-29 | 2006-11-16 | Manohar Saindane | Solid forms of a JNK inhibitor |
BRPI0811065A2 (pt) * | 2007-06-08 | 2014-12-02 | Abbott Lab | Indazóis 5-heteroaril substituídos como inibidores de quinase |
-
2011
- 2011-12-16 RS RS20160779A patent/RS55165B1/sr unknown
- 2011-12-16 PT PT118017110T patent/PT2655357T/pt unknown
- 2011-12-16 LT LTEP11801711.0T patent/LT2655357T/lt unknown
- 2011-12-16 AU AU2011347711A patent/AU2011347711B2/en active Active
- 2011-12-16 EP EP11801711.0A patent/EP2655357B1/fr active Active
- 2011-12-16 ES ES11801711.0T patent/ES2592713T3/es active Active
- 2011-12-16 BR BR112013015460-8A patent/BR112013015460B1/pt active IP Right Grant
- 2011-12-16 EA EA201300730A patent/EA023544B1/ru not_active IP Right Cessation
- 2011-12-16 PL PL11801711.0T patent/PL2655357T3/pl unknown
- 2011-12-16 CA CA2822166A patent/CA2822166C/fr active Active
- 2011-12-16 SI SI201130961A patent/SI2655357T1/sl unknown
- 2011-12-16 JP JP2013545217A patent/JP6007189B2/ja active Active
- 2011-12-16 SG SG2013046586A patent/SG191205A1/en unknown
- 2011-12-16 MX MX2013007149A patent/MX2013007149A/es active IP Right Grant
- 2011-12-16 WO PCT/EP2011/073015 patent/WO2012084704A1/fr active Application Filing
- 2011-12-16 US US13/995,803 patent/US9073892B2/en active Active
- 2011-12-16 CN CN201180061368.3A patent/CN103429585B/zh active Active
- 2011-12-16 BR BR122021014375-7A patent/BR122021014375B1/pt active IP Right Grant
- 2011-12-16 HU HUE11801711A patent/HUE029617T2/en unknown
- 2011-12-16 KR KR1020137019290A patent/KR101842098B1/ko active IP Right Grant
- 2011-12-20 AR ARP110104813A patent/AR084507A1/es active IP Right Grant
-
2013
- 2013-06-13 IL IL226912A patent/IL226912A/en active IP Right Grant
- 2013-07-19 ZA ZA2013/05483A patent/ZA201305483B/en unknown
-
2014
- 2014-05-30 HK HK14105096.6A patent/HK1191938A1/xx unknown
-
2016
- 2016-09-02 HR HRP20161127TT patent/HRP20161127T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US9073892B2 (en) | 2015-07-07 |
CA2822166C (fr) | 2019-10-29 |
SG191205A1 (en) | 2013-07-31 |
CN103429585A (zh) | 2013-12-04 |
KR20130133252A (ko) | 2013-12-06 |
AU2011347711B2 (en) | 2017-02-02 |
HUE029617T2 (en) | 2017-03-28 |
IL226912A (en) | 2017-01-31 |
PT2655357T (pt) | 2016-09-28 |
PL2655357T3 (pl) | 2016-12-30 |
HRP20161127T1 (hr) | 2016-11-18 |
BR112013015460A2 (pt) | 2016-09-20 |
LT2655357T (lt) | 2016-10-10 |
AR084507A1 (es) | 2013-05-22 |
EA023544B1 (ru) | 2016-06-30 |
JP6007189B2 (ja) | 2016-10-12 |
MX2013007149A (es) | 2013-10-30 |
US20130274241A1 (en) | 2013-10-17 |
BR122021014375B1 (pt) | 2021-11-30 |
JP2014500286A (ja) | 2014-01-09 |
CA2822166A1 (fr) | 2012-06-28 |
SI2655357T1 (sl) | 2016-10-28 |
CN103429585B (zh) | 2015-07-08 |
EA201300730A1 (ru) | 2013-12-30 |
BR112013015460B1 (pt) | 2022-01-25 |
EP2655357B1 (fr) | 2016-06-22 |
WO2012084704A1 (fr) | 2012-06-28 |
AU2011347711A1 (en) | 2013-08-01 |
EP2655357A1 (fr) | 2013-10-30 |
RS55165B1 (sr) | 2017-01-31 |
ZA201305483B (en) | 2014-06-25 |
ES2592713T3 (es) | 2016-12-01 |
KR101842098B1 (ko) | 2018-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1191938A1 (en) | Indazolyl triazole derivatives as irak inhibitors -1 | |
ZA201204959B (en) | Pyrazole derivatives as jak inhibitors | |
HK1182594A1 (en) | N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5- | |
ZA201209117B (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
EP2536697A4 (fr) | Nouveaux dérivés de triazole antifongiques | |
ZA201304282B (en) | Pyrazole derivative | |
IL223028A0 (en) | Tertrahydrocarboline derivative | |
ZA201208125B (en) | Pyrazole compounds as jak inhibitors | |
HK1185082A1 (en) | Acylbenzene derivative | |
GB2490849B (en) | Di-aspirin derivatives | |
EP2599775A4 (fr) | Dérivé d'éthinyl-pyrazole | |
EP2537831A4 (fr) | Dérivé d'imidazole | |
HK1186177A1 (en) | Novel triazole compounds iii iii | |
HK1174625A1 (en) | Pyrrazolopyridine derivatives | |
HUP1000243A2 (en) | 8-hidroxy-quinoline derivatives | |
EP2655365A4 (fr) | Dérivé de 2-carboxamide-4-pipérazinyl-benzofurane | |
HK1180971A1 (zh) | 吡唑化合物 | |
ZA201209248B (en) | Amido-tropane derivatives | |
IL220983A0 (en) | 2-aldoximino-5-fluoropyrimidine derivatives | |
AU2010901404A0 (en) | Cliplok brackets |